FTO-IN-8

Cat. No.: HY-151106

CAS No.: 2640366-38-5

Molecular Formula: $C_{19}H_{23}ClN_2O_2$

Molecular Weight: 346.85

Target: Fat Mass and Obesity-associated Protein (FTO)

Pathway: Metabolic Enzyme/Protease

Storage:

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (288.31 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	2.8831 mL	14.4155 mL	28.8309 mL
5 mM	0.5766 mL	2.8831 mL	5.7662 mL
10 mM	0.2883 mL	1.4415 mL	2.8831 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

FTO-IN-8 (FTO-43) is a N6-methyladenosine demethylase (FTO) (fat mass- and obesity-associated protein) inhibitor with the IC_{50} value of 5.5 μM. FTO-IN-8 has anti-cancer cell proliferative activity[1].

In Vitro

FTO-IN-8 (FTO-43) (0-50 μM, 24-72 h) inhibits the proliferation of cancer cells with no cytotoxicity to normal colonic cells[1].

FTO-IN-8 (FTO-43) can increase m^6A and m^6A_m levels and inhibits Wnt/PI3K-Akt signaling in gastric cancer AGS cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	AGS, SNU16, and KATOIII cell lines
Concentration:	0-50 μM
Incubation Time:	24, 48, 72 hours
Result:	Inhibited the growth of SNU16, KATOIII and AGS with the EC_{50} values of 17.7 μM, 35.9 μM

	and 20.3 μM, respectively.

REFERENCES

[1]. Sarah Huff, et al. Rational Design and Optimization of m6A-RNA Demethylase FTO Inhibitors as Anticancer Agents. J Med Chem. 2022 Aug 8.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA